Literature DB >> 2247792

The relevance of a First-World therapeutic drug monitoring service to the treatment of epilepsy in Third-World conditions.

M L McFadyen1, R Miller, M Juta, V Hodgson.   

Abstract

In May 1988 a Therapeutic Drug Monitoring (TDM) service for anti-epileptic drugs was established at Prince Mshiyeni Memorial Hospital. This service was offered as a multidisciplinary team approach involving sisters, doctors, social workers and pharmacists at an epilepsy clinic. Statistics gathered over a 13-month period showed that: (i) epileptic patient numbers increased from 52 to 211 per 4-week cycle, while patients requiring TDM decreased from 40 to 20 per cycle; (ii) phenytoin was the most frequently prescribed anticonvulsant, followed by carbamazepine and phenobarbitone, throughout the period; (iii) TDM did not alter prescribing patterns--approximately 90% of patients were on monotherapy at the beginning and at the end of the assessment period; (iv) 471 serum levels were measured in 280 patients over 13 months. Phenytoin serum levels constituted the majority (53%) followed by carbamazepine (33%), phenobarbitone (12%) and valproate (2%); (v) of the levels measured in 24 patients taking phenytoin 300 mg/d who were experiencing neither seizures nor side-effects, 38% of levels were in the potentially toxic range; and (vi) well-controlled patients increased from 36% in the first cycle to 60% in the last cycle. A TDM service is very useful in a Third-World setting and can assist in conserving scarce sources provided it is utilised within a holistic treatment framework.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2247792

Source DB:  PubMed          Journal:  S Afr Med J


  3 in total

Review 1.  Therapeutic drug monitoring and patient outcome. A review of the issues.

Authors:  A L Tonkin; F Bochner
Journal:  Clin Pharmacokinet       Date:  1994-09       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics in the 21st century. Does the evidence support definitive outcomes?

Authors:  M H Ensom; G A Davis; C D Cropp; R J Ensom
Journal:  Clin Pharmacokinet       Date:  1998-04       Impact factor: 6.447

Review 3.  Pharmacogenetics: the therapeutic drug monitoring of the future?

Authors:  M H Ensom; T K Chang; P Patel
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 5.577

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.